China Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needsChina Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs